Literature DB >> 16857348

Continuous versus intermittent levofloxacin treatment in complicated urinary tract infections caused by urinary obstruction temporarily relieved by foreign body insertion.

Peter Tenke1, Bela Kovacs, Ria Benkõ, David Ashaber, Elizabeth Nagy.   

Abstract

This study was one of the first to examine the in vivo levofloxacin adsorption to stent surfaces. The results demonstrated the ability of this antibiotic to adsorb to the conditioning film and to the surface of the inserted device, and showed that 1-2 weeks after the discontinuation of antibiotic administration some amount of the antibiotic still could be detected on them. The second aim of the investigation was to determine whether continuous or intermittent levofloxacin treatment is advantageous for the patients who have acute complicated urinary tract infection (UTI) caused by urinary obstruction. The results did not show any clinical or microbiological advantages of the continuous therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16857348     DOI: 10.1016/j.ijantimicag.2006.05.016

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  4 in total

Review 1.  Renal struvite stones--pathogenesis, microbiology, and management strategies.

Authors:  Ryan Flannigan; Wai Ho Choy; Ben Chew; Dirk Lange
Journal:  Nat Rev Urol       Date:  2014-05-13       Impact factor: 14.432

Review 2.  Ureteral stent symptoms and associated infections: a biomaterials perspective.

Authors:  Ben H Chew; Dirk Lange
Journal:  Nat Rev Urol       Date:  2009-07-14       Impact factor: 14.432

Review 3.  Consensus of multiple national guidelines: agreed strategies for initial stone management during COVID-19.

Authors:  B Heijkoop; E Galiabovitch; N York; D Webb
Journal:  World J Urol       Date:  2020-11-23       Impact factor: 4.226

4.  Endourological Stone Management in the Era of the COVID-19.

Authors:  Silvia Proietti; Franco Gaboardi; Guido Giusti
Journal:  Eur Urol       Date:  2020-04-14       Impact factor: 20.096

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.